Back to School: How biopharma can reboot drug development. Access exclusive analysis here
This month, AesRx will begin a double-blind, placebo-controlled Phase II trial to evaluate Aes-103 for 28
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury